-+ 0.00%
-+ 0.00%
-+ 0.00%

Rocket adopts severance, change-in-control program for US employees, executives

PUBT·08/27/2026 20:10:54
Listen to the news
Rocket adopts severance, change-in-control program for US employees, executives
  • Rocket Pharmaceuticals adopted a severance and change-in-control program on Aug. 21, 2026 for most U.S. employees.
  • CEO qualifying termination: 15 months base salary, benefits continuation; change-in-control window: 18 months base salary, target bonus, prorated target bonus.
  • Section 16 officers: 12 months base salary outside change in control; change-in-control: 12 months base salary, target bonus, prorated target bonus.
  • CEO Gaurav Shah employment agreement set base salary at USD 674,856; target annual incentive bonus at 60% of base salary.
  • General Counsel Martin Wilson base salary set at USD 547,313; target annual incentive bonus at 45% of base salary.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-034689), on August 27, 2026, and is solely responsible for the information contained therein.